Alicanto® is an antibody discovery service that harnesses decades of technology development across genomics and proteomics. We use mass spectrometry and next-generation sequencing to identify high affinity monoclonal antibodies from serum.
Alicanto® uses mass spectrometry combined with next-generation sequencing to identify the highest affinity antibodies that have been selected by the native immune system. Our technology is flexible, and can be applied to a variety of host organisms, including rabbit, human, and llama.
We measure the success of our immunization using the serum antibody titer. Once we know that antibodies with the desired functionality are present in the serum, why would we look anywhere else?
Our antibodies can be used for a wide array of applications including as therapeutics, diagnostics, and research tools. Unlike single B cell, hybridoma, or B cell cloning approaches that leave screening until the end stages, we build the desired antibody properties into the earliest stages of the process.
This allows us to de-risk a project early, and deliver high quality antibody sequences to you faster.
Alicanto® can be applied to any species with a backbone and a jaw, as long as a sufficient antibody response can be generated to your target.
Sequences – A set of up to 10 heavy chain sequences and 10 light chain sequences selected by Alicanto®.
Interactive report – An interactive, web-based report of the entire dataset to investigate individual antibodies, clonal families, and repertoire-wide features.
Transparency – Full access to the repertoire raw data and data tables.
Expressed antibodies – 1mg of up to 10 antibodies validated by ELISA.
